Observational studyDeutsches Arzteblatt international2026
Transcatheter Aortic Valve Implantation: Selection, Early Mortality, and Complications. A Multicenter Evaluation of More Than 33 000 Implantations (2013–2023).
Observational study in Deutsches Arzteblatt international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve implantation (TAVI) has become the standard treatment of persons aged 75 and above with severe aortic valvular stenosis. In this study, we analyzed temporal trends in risk profiles and treatment results from 2013 to 2023.
methodsWe carried out a retrospective analysis of patient characteristics, periprocedural complications, and 30-day mortality after 33 079 TAVI procedures that were carried out in seven German cardiac care centers.
resultsTAVI case numbers rose from 1605 in 2013 to 4459 in 2023. The mean age of the patients remained constant at 81 years, while the operative risk (STS score) fell from 5.9% to 4.1%. The percentage of low-risk patients (STS < 4%) rose from 47% to 66%. From 2013 to 2023, there was a steady decline in periprocedural complications including severe bleeding of VARC types 3 and 4 (8.5% to 2.9%), vascular complications (17.2% to 4.9%), stroke (4.2% to 2.1%), and pacemaker implantations (15.5% to 11.4%). Over the same period, the risk-adjusted 30-day mortality fell from 3.8% to 3.2%.
conclusionThe improved short-term results of TAVI from 2013 to 2023 are attributable to a change in patients' risk profiles as well as the increasing experience of the interventionists and refinements of the procedure. The mortality rate, which has remained unchanged in recent years, indicates that the care of older patients with severe aortic stenosis has been largely optimized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.